Ravulizumab treatment outcomes in patients with Generalized Myasthenia Gravis

Trial Identifier: D9281R00004
Sponsor: AstraZeneca
Start Date: May 2025
Primary Completion Date: December 2029
Study Completion Date: December 2029

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Poland BYDGOSZCZ, Poland
Poland GDAŃSK, Poland
Poland KATOWICE, Poland
Poland KRAKÓW, Poland
Poland ŁÓDŹ, Poland
Poland LUBLIN, Poland
Poland SZCZECIN, Poland
Poland WARSZAWA, Poland
Poland WROCŁAW, Poland